FAMI
NBIX icon

Fideuram Asset Management (Ireland)’s Neurocrine Biosciences NBIX Stock Holding History

Fideuram Asset Management (Ireland)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$796K Buy
+4,922
New +$730K 0.02% 620
2026
Q1 		– Sell
-19
Closed -$2.71K – 631
2025
Q4 		$2.71K Buy
+19
New +$2.75K ﹤0.01% 621

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Fideuram Asset Management (Ireland)'s NBIX Position: Q2 2026 in Review

Fideuram Asset Management (Ireland) opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 4,922 shares worth $796K. The stake represents 0.02% of the portfolio and ranks #620 among its holdings. This is a return to the name: Fideuram Asset Management (Ireland) previously reported a position in NBIX as recently as Q4 2025.

Fideuram Asset Management (Ireland) first reported a position in NBIX in Q4 2025 and has held it in 2 quarters since. 473 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Fideuram Asset Management (Ireland) held 4,922 shares of Neurocrine Biosciences worth $796K as of Q2 2026.
  • Neurocrine Biosciences was a new Fideuram Asset Management (Ireland) position in Q2 2026.
  • Neurocrine Biosciences made up 0.02% of Fideuram Asset Management (Ireland)'s portfolio in Q2 2026, its #620 holding.
  • Fideuram Asset Management (Ireland) first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 473 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Fideuram Asset Management (Ireland)'s 13F filing for Q2 2026, filed 23 Jul 2026.